J&J intercepts Nextera
How Nextera technology could enable J&J to intercept RA before it starts
Johnson & Johnson's option deal with Nextera A/S could add another tool to the pharma's growing arsenal of T cell-based technologies for intercepting immunological diseases before they start.
On Sept. 21, Nextera granted J&J's Janssen Biotech Inc. unit an option to exclusively license the biotech's Phagemer technology for rheumatoid arthritis. Janssen initially will fund a research program. Additional details of the deal, including what triggers the option, were not disclosed.
Phagemer uses phage display of recombinant major histocompatibility complex (MHC) class II molecules to screen for T cell targets of interest. MHC class II molecules on antigen-presenting cells